Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)

Clinical trial NCT02070757 · COMPLETED

Trial details

NCT number: NCT02070757
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Healthcare-Associated Pneumonia Ventilator-Associated Pneumonia Lung Diseases

Start date: 2014-09-02
Primary completion: 2018-05-15
Enrollment: 726

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.